GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Rating:
Mkt Perform
SRPT

Sarepta Therapeutics Inc (SRPT) rated Mkt Perform with price target $20 by FBR Capital

Posted on: Tuesday,  Nov 12, 2013  3:25 PM ET by FBR Capital

Sarepta Therapeutics Inc (NASDAQ: SRPT)
rated Mkt Perform with price target $20 by FBR Capital.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

FBR Capital uses a highly disciplined analysis focused on intrinsic value, which we developed to critically examine the capital structure of the companies we cover, as well as their competitive positions and the growth opportunities within their industries. We apply this discipline – which helps us assess how effectively a company’s managers deploy the capital entrusted to them – not only in our published research but also when making investing and underwriting judgments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/12/2013 3:25 PM Hold
None
12.63 20.00
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/30/2013 8:25 AM Hold
None
41.32 48.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy